SCHEMBL129591

SCHEMBL129591

[CH2]Cc1cccc(C(C)(C)O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
CETP P11597 2/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
CYP2C9 P11712 1/20 0.36
ACP3 P15309 1/20 0.36
TAAR1 Q96RJ0 1/20 0.35
PGK1 P00558 1/20 0.35
PGK2 P07205 1/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
ATM Q13315 1/20 0.34
IDO1 P14902 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2538579 0.83 ACHE (0.43) CYP1A2CYP2C19HTR2AHTR2CHTR2B
SCHEMBL548707 0.83 CYP1A2 (0.42) CYP1A2CYP2C19CYP4F2CYP4A11LMNA
SCHEMBL18802729 0.83 TAAR1 (0.46) CYP1A2CYP2C19CYP4F2CYP4A11CETP
SCHEMBL129592 0.83 KIF11 (0.46) CYP1A2CYP2C19CYP4F2CYP4A11CETP
SCHEMBL2636462 0.82 PDK1 (0.44) CYP1A2CYP2C19CYP4F2CYP4A11LMNA
SCHEMBL23501574 0.80 CYP1A2 (0.44) CYP1A2CYP2C19CYP4F2CYP4A11LMNA
SCHEMBL13316137 0.80 CYP4F2 (0.42) CYP1A2CYP2C19CYP4F2CYP4A11LMNA
SCHEMBL18802813 0.80 TAAR1 (0.43) CYP1A2CYP2C19CYP4F2CYP4A11CETP
SCHEMBL1908518 0.80 ENPP2 (0.50) CYP1A2CYP2C19CYP4F2CYP4A11HTR2A
SCHEMBL7158092 0.80 CETP (0.40) CYP1A2CYP2C19CYP4F2CYP4A11LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD K.K. (JP) 2010-08-19 US disclosed
US-7595316-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-29 US disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2006-08-10 US disclosed
EP-1642898-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative HRH3, HRH4, HCRTR2 CYP1A2 656/4885CYP2C19 746/4885CYP4F2 560/4885
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE HRH3, HRH4, HRH2 CYP1A2 327/4885CYP2C19 401/4885CYP4F2 467/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 CYP1A2 84/4885CYP2C19 44/4885CYP4F2 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.